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Sanger sequencing remains suffi-
cient when only a few samples are
analyzed and only the NA gene is
sequenced.
With the development of new an-
tivirals that also target other pro-
teins than the NA protein, resis-
tance mutations could arise across
the whole genome. In this case,
sequencing only the NA segment
will not be sufficient anymore and
NGS will be the better option.
NGS opens the possibility to
analyze the minority variants pre-
sent in the sample. This could give
the possibility to detect the emer-
gence of antiviral resistance at an
early stage.Next-generation sequencing (NGS) can enable a more effective response to a wide range of
communicable disease threats, such as influenza, which is one of the leading causes of human
morbidity and mortality worldwide. After vaccination, antivirals are the second line of defense
against influenza. The use of currently available antivirals can lead to antiviral resistance muta-
tions in the entire influenza genome. Therefore, the methods to detect these mutations should
be developed and implemented. In this Opinion, we assess how NGS could be implemented to
detect drug resistance mutations in clinical influenza virus isolates.
What Is the Importance of Genetic Influenza Surveillance with Regard to Antiviral
Resistance?
One of the major technological evolutions in life sciences of the past decade is next-generation
sequencing (NGS; seeGlossary). This technology could enable amore effective response to awide range
of communicable disease threats, such as influenza viruses. A major advantage of whole-genome
sequencing (WGS) is that this one technique can provide broad anddetailed data on the identify of path-
ogens that previously required multiple laboratory phenotypic and genotypic assays. Moreover, WGS
provides higher resolution information than conventional genotyping tests. qRT-PCR and Sanger
sequencing, for example, are often targeted to a limited fraction of the genome, meaning that crucial
information can bemissed. The additional genotypic information thatWGS can provide, could be critical
when tracking the origin of outbreaks and to forecast the spread of disease. Influenza A and B viruses are
a major cause of respiratory tract infections in humans, resulting in significant morbidity andmortality [1].
The genome of these viruses consists of eight segments of single-stranded RNA of negative polarity.
Influenza viruses can mutate rapidly when subjected to selection pressures, such as immunity induced
by prior or vaccination [2] or antiviral drug use [3]. The hemagglutinin (HA) and neuraminidase (NA) pro-
teins are often considered to be themost important viral antigens, because they are major targets of the
immune system. HA and NA are used as targets for current anti-influenza strategies: HA is the prime
target of the currently licensed influenza vaccines, and NA inhibition is the main mechanism of the
most frequently used influenza antivirals. Although vaccines are considered the best way to prevent influ-
enza, the limited use and their generally poor effectiveness in the elderly [4] (https://www.cdc.gov/flu/
about/qa/vaccineeffect.htm) imply that efficient antiviral drugs are needed as a complementary or alter-
native line of defense.
Monitoring and detecting mutations in the influenza virus genome, especially those that confer antiviral
resistance, is of paramount importance to public health surveillance (https://www.who.int/influenza/
gisrs_laboratory/antiviral_susceptibility/nai_genotyping_molecular/en/). As the use of antiviral drugs
continues to grow, more cases of drug-resistant viruses are expected to occur. Because of this, and
the fact that a limited number of anti-influenza drugs with different mechanisms are currently available,
it is important to assess whether the use of NGS could add value for the preparedness and response to
the emergence of antiviral resistance. The determination of full influenza genomes, which is possible by
more extensive use of NGS, will allow for a better understanding of the genetic determinants of viral
resistance, and may enable the detection of minority drug resistant viral populations.
In this Opinion, we provide an overview of the potential antiviral drug resistance mutations in influ-
enza virus genome, based on a thorough review of the literature on antiviral drugs that target
different stages of the viral life cycle (Figure 1).Trends in Biotechnology, --, Vol. --, No. -- https://doi.org/10.1016/j.tibtech.2019.09.009




overlap a certain location in the
genome. The number of times a
nucleotide at a particular position
in the genome has been read is
defined as the coverage.
Hemagglutinin (H) and Neur-
aminidase (N): both influenza A
and B have H and N proteins that
cover the surface of the viral en-
velope. Influenza A viruses are
divided into subtypes based on
the structure and antigenicity of
these two proteins. Among influ-
enza A viruses there are 18
different types of hemagglutinin
and 11 different types of neur-
aminidase. Each virus has one
type of H (H1–H18) and one type
of N (N1–N11).
Next-generation sequencing
(NGS) or high-throughput or
massively parallel or deep
sequencing:: description of DNA
sequencing technologies that can
produce millions or billions of
short reads in parallel, such as Il-
lumina. Each position is
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Different methods can be used to identify the appearance of antiviral drug resistance. Screening vi-
ruses in clinical samples for antiviral resistance using a specific phenotypic assay is the first method
that can be used, but this implies that the antiviral drug is already commercially available and in
use. Phenotypic assays can evaluate the production of virus particles in the presence of the antiviral
drug in comparison to mock-treated conditions (total amount of virus using for example ELISA-based
methods, or infectious particles using for example plaque reduction assays), or the activity of the
enzyme/protein targeted by the antiviral (NA-inhibition assay for example).
Other approaches, such as serial passages in cell culture or in animal models [5,6], are useful to eval-
uate new compounds and potential appearance of resistance. In both cases, the associated muta-
tions can then be identified by sequencing the viral genome. Structural analyses can also be used
to determine amino-acid substitutions that would likely confer resistance. Using site-directed muta-
genesis and reverse genetics systems, these theoretical mutations can be tested to confirm the resis-
tance in phenotypic assays [7].
More than 200mutations in the influenza virus genome reportedly confer antiviral drug resistance. For
each mutation (Table S1 in the supplemental information online), the mechanism that explains the
conferred resistance (if known) and the origin of that used to identify these mutations (e.g., clinical
sample, reverse genetics, or serial passaging) are provided. Oseltamivir and zanamivir, two NA-activ-
ity inhibitors, are currently the most commonly used antiviral drugs; it is thus not surprising that the
majority of the mutations were found in the NA segment (see Figure S1 in the supplemental informa-
tion online). Mutations detected in patients and reported in more than five papers that induce resis-
tance against commercially available antivirals or antivirals in clinical trials were included in a table of
antivirals (see Table S2 in the supplemental information online).
sequenced multiple times, which
provides a high depth of coverage
to deliver accurate data and an
insight into nucleotide sequence
variation.
Reverse genetics: to understand
the function of a gene, reverse
genetics tries to identify which
phenotypes arise because of
particular genetic sequences. A
gene sequence is known and then
the phenotype is investigated.
Site-directed mutagenesis: spe-
cific and intentional introduction
of nucleotide sequence changes
in a DNA or RNA molecule. This
way, the impact of certain genetic
changes (insertions, deletions,
substitutions) can be investigated
with reverse genetics.
Viral quasispecies: sub-
populations present in a biolog-
ical sample that carries low fre-
quency variants. The RNA viral
genomes typically exhibits high
mutation rates, which leads to a
heterogeneous population within
the same patient, each with spe-
cific evolutionary properties.
Virion: free viral particle that con-
sists of an RNA or DNA core with a
protein coat and sometimes with
an external envelope, which is a
lipid bilayer.Detection of Antiviral Resistance Mutations: From Classical Surveillance to the
Implementation of NGS
Once a mutation has been identified that confers resistance to an antiviral drug, it is important to be
able to rapidly detect and follow its possible emergence in circulating strains. Although phenotypic
tests remain the only way to confirm the resistance of the virus, genotypic assays are the most
commonly used in clinical samples because they provide a rapid method to detect known mutations
and eliminate the need for virus isolation and propagation in cell cultures (Table 1) [8–12]. In addition,
if loaded into an in-house bioinformatics pipeline or another web-based application, these known
mutations can be rapidly identified.
Genotyping by qRT-PCR is commonly used as a fast and relatively inexpensive method that can be
performed directly on clinical specimens [8,13]. However, this approach can only detect one targeted
mutation, as it relies on limited differences in the genome. qRT-PCR can thus be difficult to develop
and it has limited benefits in the context of surveillance [8,14,15].
Sanger sequencing is still used as a standard reference method for routine genetic surveillance of
influenza viruses. However, the viral RNA genome must first be extracted, and the genomic segment
of interest must be amplified by RT-PCR. Each Sanger sequencing reaction is based on one single
primer pair and provides a sequence of 400–1000 bases in length [16,17]. To obtain the sequence
of an entire segment or even the whole influenza genome (approximately 14 kb), multiple primers
must be used in parallel reactions [18]. Sanger sequencing thus becomes labor intensive and can
be expensive if the whole genome sequence of a large set of samples is required [8,14,19].
Sanger-based technologies are also not the most suitable methodologies to detect polymorphisms
or minority variants with a frequency lower than 20% [20–22].
The beginning of the 21st century has seen a gradual shift from Sanger sequencing towards newer,
NGS (also known as second-generation sequencing) methods that allow a higher throughput at a
relatively low cost [17,23]. For these technologies, targeted RT-PCRmight still be necessary to amplify2 Trends in Biotechnology, --, Vol. --, No. --
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in the sample. In 2005, Bright and colleagues were the first to use a pyrosequencing platform to
monitor the emergence and spread of adamantane resistance in circulating A(H3N2) influenza virus
strains over a 10-year period [24]. Pyrosequencing has since been successfully used to detect already
knownmutations in NA andM2, responsible for antiviral resistance. However, different sets of primers
are required to detect these mutations [25].
NGS platforms remain the best choice in terms of value for money for high-throughput sequencing.
NGS can be accomplished with several methodologies, namely sequencing-by-ligation (SOLiD tech-
nology), sequencing-by-hybridization (resequencing microarray), and sequencing-by-synthesis (Illu-
mina, Ion Torrent; now the dominant nucleic acid technology) [17,26,27]. NGS methods generate
massive numbers of reads that are 75–700 bases in length but with a high coverage per base. Such
parallel, deep sequencing allows for the reconstruction of the entire genome in a sample. NGS
also provides the ability to detect quasispecieswith a frequency below 20%. Van den Hoecke and col-
leagues arbitrarily proposed the use a threshold of 0.5% for Illumina MiSeq and Ion Torrent, below
which it becomes too difficult to distinguish real mutations from background errors cumulatively
introduced by the RT-PCR and the sequencing technology itself [28].
However, NGS methods come with several limitations: the short-read length requires powerful bio-
informatic algorithms to assemble a consensus sequence, and the required amplification by RT-PCR may
introduce biases. Third-generation sequencersmay address these problems, by constructing longer reads
and possibly eliminating the requirement for amplification of the virus [29]. However, the low abundance of
virus inmost clinical respiratory samples and the relative novelty of these approaches currently still makes it
difficult to eliminate RT-PCR amplification. The twomain approaches for third-generation sequencing [30]
are the synthetic approach that relies on existing short-reads technologies to construct long reads [26,31]
and the single-molecule-real-time sequencing approach (SMRT) [32]. The SMRT approach is the most
widely used and is represented by sequencing technologies developed by Pacific Biosciences (PacBio)
andOxfordNanopore [33–35]. PacBio is able to generate long reads, which enables the analysis of difficult
regions with multiple repeats. In addition, the real-time acquisition of the signal means that there is no lag
between each nucleotide addition. However, the PacBio flow cell is not as high-throughput as the Illumina
platform and the error rate is still relatively high in comparison to the Illumina platform [26,30,36–39]. So far,
only a limited number of publications have reported on the use of PacBio on clinical human influenza virus
samples or on influenza viruses generated with reverse genetics [39–41]. The MinION from Oxford Nano-
pore is a small device that has a relatively low cost and can provide very long reads. Currently, oneMinION
studyhasuseddirectRNAsequencingof the influenzavirusgenome,withoutprior amplificationbyRT-PCR,
but this was only feasible because of a very high viral load, which is rarely found in clinical samples [42–46].
The elimination of RT-PCR amplification may lead to a lower cost and a shorter execution time. MinION
reads are still characterized by a lower quality with high error rates, and therefore a high depth coverage
is necessary to detect antiviral resistance mutations with confidence [45].CasesWhenNGSCouldHaveAddedValue for Detection of Drug-ResistanceMutations
High-throughput molecular approaches offer new possibilities for influenza virus surveillance. By
determining the whole-genome of the influenza virus, higher resolution evolutionary patterns can
be revealed, knowledge of reassortment events and emerging mutations across all genes can be pro-
vided and information on intrahost diversity of the virus (quasispecies) can be obtained. This informa-
tion can lead to a better understanding of genetic changes in all segments for various seasons,
tropism markers, antigenic characteristics, virulence, reassortment events, and of course antiviral
resistance [40,42,47–51].Monitoring and Surveillance of Resistance to New Antiviral Drugs
Currently, adamantanes and NA inhibitors, which includes oseltamivir and zanamivir, or a combina-
tion of antivirals, are the only antiviral drugs for influenza viruses licensed in Europe. Adamantanes,
however, are not used anymore due to the presence of resistance mutations in almost all currently





































Figure 1. Antiviral Drugs against Influenza Virus and Their Target Sites in the Virus Cycle.
The different stages of the viral cycle are the binding of HA to the sialic-acid containing host receptor (A), followed by the endocytosis and the acidification of
the HA protein (B). This acidification in the early endosomes leads to fusion of the viral and endosomal membranes, and triggers the influx of H+ ions through
the M2 channel that results in the dissociation of the vRNPs and uncoating (C). After transport of the vRNPs to the nucleus, viral mRNA synthesis is initiated by
the viral polymerase. The latter is also responsible for the unprimed replication of the vRNA through a cRNA intermediate (D). The viral mRNAs are exported
to the cytoplasm and translated into viral proteins. In the endoplasmic reticulum, the surface proteins HA, M2, and NA are processed, glycosylated, and
transported to the cell membrane (E). The newly synthesized vRNPs are transported to the cytoplasm, mediated by an M1–NS2 complex that is bound
to the vRNP (F). At virion assembly and budding sites, the newly produced vRNPs are incorporated into new viruses. Finally, the NA cleaves these sialic
acid residues and virions are released from the host cell (G). The figure illustrates the different antiviral drugs at the position where they interfere with
the viral cycle. Between brackets the number of mutations that are known to be related to antiviral resistance are indicated to the different antiviral
drugs. Abbreviations: HA, hemagglutinin; NA, neuraminidase: vRNP, viral ribonucleoprotein.
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Trends in Biotechnologymay not be required, as Sanger sequencing of the NA segment is probably sufficient for the surveil-
lance of antiviral emergence.
Although NA inhibitors are licensed to treat uncomplicated influenza infection, they are, in most
European countries, only used to treat patients at risk of developing more serious complications,
such as the elderly or people with underlying conditions (https://ecdc.europa.eu/en/seasonal-
influenza/prevention-and-control/antivirals/faq). However, the need to carefully monitor seasonal
influenza virus susceptibility to NA inhibitors remain a priority for public health agencies. At
present, the percentage of detected circulating NA inhibitor-resistant viruses is low, but as seen in
the 2007–2008 influenza season in Europe for the seasonal A(H1N1) strain, there can be a sporadic4 Trends in Biotechnology, --, Vol. --, No. --
Benefits Challenges NGS
platform






























NA 24 400–1000 0.001 US$ 10 000 000




















Illumina 27–144 36, 75, 100,
150, 250, 300
0.1–1 US$ 7–2000
Ion torrent 2–7.5 200–400 1–2 US$ 80–2000
PacBio 0.5–60 10 000–20 000 14–15 US$ 600–1000
Oxford
nanopore
<48 <200 000 5–40 US$ 100–400
Table 1. Comparison of Different Genotypic Assays
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from that season were resistant to oseltamivir [52]. By the 2008–2009 season the number of resistant
influenza A(H1N1) strains had increased to 98% [53]. This raised concerns until the extinction of this
A(H1N1) subtype following the emergence of the susceptible A(H1N1pdm09) pandemic virus in
2009. Some mutations that confer antiviral resistance cause a decrease in fitness of the resistant vi-
ruses. However, several studies have shown that compensatory mutations may coemerge and
improve the fitness of the resistant viruses. These mutations can also arise during cell culture, which
led to the CDC’s Influenza Division and WHO Collaborative Centers to shift to a sequencing first
approach using NGS before performing isolation and phenotypic characterization on a subset of
samples [54].
As antivirals directed against other influenza virus proteins gradually become approved and used in
the population, the need to monitor possible resistance mutations in other parts of the viral genome
becomes more important (Table S1 and S2 in supplemental information online). For example, Xofluza
(baloxavir marboxil) was recently approved in the US and Japan. This drug is a cap-dependent
endonuclease inhibitor of the viral polymerase acidic (PA), for which a resistance mutation in the
PA segment has already been found in clinical samples. Favipiravir, which targets the viral RNA-
dependent RNA polymerase (RdRP), is available in Japan for patients infected by an influenza virus
that is resistant to other available influenza drugs and it is in the third phase of clinical trials in the
US and Europe. Recently, a substitution in the PB1 segment, namely K229R, was reported in an
in vitro study to confer resistance to favipiravir. This substitutions was accompanied with a PA
P653L substitution, which restores the fitness of the virus [55]. In the Russian Federation and China,
umifenovir (Arbidol) is used to treat influenza. This broad-spectrum antiviral can prevent virus entry
into the host cell and is believed to target the HA protein. Other antivirals, such as nitazoxanide,
an HA maturation inhibitor and pimodivir, a PB2 inhibitor, are being evaluated in phase III clinical
trials. No specific, easy, standardized phenotypic tests have been developed yet to monitor theTrends in Biotechnology, --, Vol. --, No. -- 5
Outstanding Questions
Is it possible to reduce the cost and
develop easy-to-use bioinformatics
tools to help implement NGS in
routine influenza surveillance in the
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able. WGS is of interest since most of these new drugs target viral proteins involved in the replication
pathways where multiple viral proteins usually cooperate. In a few in vitro studies, resistance substi-
tutions appeared in other proteins rather than in the target protein of the antiviral drug (Figure S1 in
supplemental information online) [56].near future?
Is it possible to integrate the ge-
netic sequence of influenza virus
obtained by the NGS with the pa-
tient information for a better indi-
vidual follow-up of the patient?
Will the detection of minority vari-
ants allow to foresee if a patient will
rapidly develop mutations confer-
ring antiviral resistance?
How could the limitations of third
generation sequencers be over-
come to allow the analysis of clin-
ical viral samples like influenza in
the future?Surveillance of Emergence of Resistance Mutations in Quasispecies
With traditional sequencing approaches, it is difficult to detect and quantify minority genomes pre-
sent in viral quasispecies. NGS provides, for each patient, the possibility to investigate previously
inaccessible aspects of viral dynamics [57]. The challenge in characterizing quasispecies composition
remains to define a cut-off between real mutations and false positives.
Influenza virus quasispecies analysis in the context of antiviral resistance has already been performed
in clinical samples in a few studies. Trebbien and collaborators [58] followed for 6 months an immu-
nocompromised patient treated with oseltamivir and zanamivir. They concluded that NGS was neces-
sary to properly investigate the complex population at the sites that are considered important for
antiviral resistance. Similarly, Pichon and colleagues [59] followed a child with severe combined
immunodeficiency. The authors concluded that NGS allowed for the characterization of viral variant
evolution and that the quasispecies analysis could reveal a risk of decreased antiviral efficacy. These
study cases clearly indicate that the characterization of the quasispecies composition of influenza
virus genome could reveal the emergence of antiviral resistance. NGS technologies provide the
necessary tools to detect the appearance and emergence of resistance mutations as quasispecies,
either by studying samples from a patient under treatment or by analyzing a large set of circulating
viruses, and thus to identify these mutations before they reach a proportion where they can affect the
antiviral susceptibility phenotype or before they become dominant.Concluding Remarks and Future Perspectives
Monitoring the antiviral drug susceptibility of influenza virus has long focused on the NA protein,
because NA inhibitors have historically been the most extensively used anti-influenza drugs. Howev-
er, as new antivirals that target different viral proteins become available and used to treat influenza
patients, the need to obtain information about the whole genome increases. Therefore, NGS repre-
sents a more informative approach than Sanger sequencing in the context of routine surveillance.
This routine surveillance usingWGS remains challenging regarding the complexity of data analysis for
non-bioinformatics experts. Although, there are many tools available to analyze NGS results, many of
these require substantial bioinformatic expertise because they are only available using the command
line on Linux. Therefore, the spread of more web-based platforms with a user-friendly interface within
the scientific community would be an advance in the use of WGS for non-bioinformatic experts [60].
The development of these NGSmethods has provided an opportunity to obtain information about all
the genomic segments and about theminority genomes present in viral quasispecies. Investigation of
this quasispecies nature of influenza viruses thus improves preparedness by potentially forecasting
the emergence of resistance substitutions.
However, despite intensive research on influenza viruses, little is still known about the role, dy-
namics, and spread of viral quasispecies. More work is needed to understand whether and how
the quasispecies nature of influenza viruses plays a role in antiviral escape and in immune selection
pressure, or whether this could be a contributing factor to disease severity. The use of WGS in
routine surveillance will enable a better understanding of the association of the viral quasispecies
and the host characteristics of a patient. It could also enable a quicker response when certain mu-
tations that confer antiviral resistance are emerging within the patient. The interpretation of this
genomic data is of course highly dependent on how complete and structured the epidemiological
and clinical metadata is.6 Trends in Biotechnology, --, Vol. --, No. --
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Trends in BiotechnologyUse of NGS technology also comes with limitations including the cost, the requirement to amplify the
genome, which introduces PCR errors, and the short-read lengths that require powerful bioinformatic
tools to assemble a consensus sequence. Soon third-generation sequencers may become available
and address some of these limitations by simplifying data analysis and lowering costs (see
Outstanding Questions).
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